eczema

Eli Lilly unveils new data from atopic dermatitis therapy trials
Eli Lilly unveils new data from atopic dermatitis therapy trials
Clinical Trials Arena
Eli Lilly
clinical trial
eczema
atopic dermatitis
lebrikizumab
Flag link:
Leo Pharma announces positive results for hand eczema study
Leo Pharma announces positive results for hand eczema study
Pharmaphorum
LEO Pharma
clinical trials
eczema
chronic hand eczema
delgocitinib
Flag link:
One down, one to go: Arcutis' repurposed AstraZeneca drug clears first PhIII eczema trial
One down, one to go: Arcutis' repurposed AstraZeneca drug clears first PhIII eczema trial
Endpoints
Arcutis Biotherapeutics
eczema
clinical trials
roflumilast
Flag link:
Despite recent progress, Incyte still far off from pricing goal for key eczema launch Opzelura
Despite recent progress, Incyte still far off from pricing goal for key eczema launch Opzelura
Fierce Pharma
Inctye
Opzelura
eczema
Flag link:
Pfizer discards eczema, NASH and breast cancer programs in early-phase clean-out
Pfizer discards eczema, NASH and breast cancer programs in early-phase clean-out
Fierce Biotech
Pfizer
R&D
NASH
breast cancer
eczema
Flag link:
Incyte's Opzelura slapped with vitiligo delay amid topical JAK's eczema launch
Incyte's Opzelura slapped with vitiligo delay amid topical JAK's eczema launch
Fierce Pharma
Incyte
Opzelura
eczema
vitiligo
Flag link:
Novartis JAKs in rival to Incyte's topical eczema drug after seeing clinical data
Novartis JAKs in rival to Incyte's topical eczema drug after seeing clinical data
Fierce Biotech
Novartis
Incyte
JAK inhibitors
Opzelua
eczema
atopic dermatitis
Flag link:
Eli Lilly, Incyte axe Olumiant in lupus amid eczema stalemate at FDA
Eli Lilly, Incyte axe Olumiant in lupus amid eczema stalemate at FDA
Fierce Pharma
Eli Lilly
Incyte
olumiant
FDA
lupus
eczema
Flag link:
Connect Biopharma celebrates a mid-stage win for its Dupixent rival, but shares tank after investors clamor for data
Connect Biopharma celebrates a mid-stage win for its Dupixent rival, but shares tank after investors clamor for data
Endpoints
Connect Biopharma
Dupixent
China
eczema
clinical trials
Flag link:
Sanofi, Regeneron plot Dupixent filing in young eczema patients, advancing drug's megablockbuster ambitions
Sanofi, Regeneron plot Dupixent filing in young eczema patients, advancing drug's megablockbuster ambitions
Fierce Pharma
Sanofi
Regeneron
Dupixent
eczema
pediatric
Flag link:
Connect Biopharma celebrates a mid-stage win for its Dupixent rival, but shares tank after investors clamor for data
Connect Biopharma celebrates a mid-stage win for its Dupixent rival, but shares tank after investors clamor for data
Endpoints
Connect Biopharma
China
eczema
clinical trials
CBP-201
Dupixent
Flag link:
A Pfizer Drug Moves Closer to Approval in Another Important Indication
A Pfizer Drug Moves Closer to Approval in Another Important Indication
Motley Fool
Cibingo
Pfizer
Europe
eczema
atopic dermatitis
Flag link:
AbbVie, Janssen, Novartis, Pfizer and UCB to jointly advance 'digital' endpoint for atopic dermatitis
AbbVie, Janssen, Novartis, Pfizer and UCB to jointly advance 'digital' endpoint for atopic dermatitis
Endpoints
atopic dermatitis
eczema
nocturnal scratch
digital endpoint
AbbVie
Janssen
JNJ
Novartis
Pfizer
UCB Pharma
digital pharma
Flag link:
Amgen reveals midphase eczema data behind its $400M bet
Amgen reveals midphase eczema data behind its $400M bet
Fierce Biotech
Amgen
Kyowa Kirin
clinical trials
eczema
antibodies
Flag link:
Key drug in Sanofi’s $1.45bn Kymab buyout shows promise in eczema
Key drug in Sanofi’s $1.45bn Kymab buyout shows promise in eczema
Pharmaforum
Sanofi
eczema
M&A
Kymab
KY1005
clinical trials
Flag link:
Pfizer gets first approval, in UK, for Xeljanz follow-up Cibinqo
Pfizer gets first approval, in UK, for Xeljanz follow-up Cibinqo
Pharmaforum
Pfizer
Cibinqo
atopic dermatitis
eczema
UK
Xeljanz
Flag link:
Cara's stock tanks as atopic dermatitis phase 2 misses endpoint
Cara's stock tanks as atopic dermatitis phase 2 misses endpoint
Fierce Biotech
Cara Therapeutics
atopic dermatitis
eczema
clinical trials
Korsuva
Flag link:
FDA hits Leo Pharma with a CRL for what the biotech says are questions about the 'device component' of eczema candidate
FDA hits Leo Pharma with a CRL for what the biotech says are questions about the 'device component' of eczema candidate
Endpoints
LEO Pharma
FDA
atopic dermatitis
eczema
monoclonal antibodies
Dupixent
Flag link:
FDA pushes eczema decision for Eli Lilly's Olumiant, Pfizer's abrocitinib back 3 months — raising more questions for the JAK class
FDA pushes eczema decision for Eli Lilly's Olumiant, Pfizer's abrocitinib back 3 months — raising more questions for the JAK class
Endpoints
FDA
JAK inhibitors
Eli Lilly
olumiant
Pfizer
abrocitinib
eczema
Flag link:
Incyte Says FDA Grants Priority Review For Eczema Cream
Incyte Says FDA Grants Priority Review For Eczema Cream
Yahoo/SmarterAnalyst
Incyte
eczema
FDA
priority review
ruxolitinib
Flag link:

Pages